New strategies in Hodgkin lymphoma: Better risk profiling and novel treatments

Clinical Cancer Research

Volumn 19, Issue 11, 2013, Pages 2797-2803

  Diefenbach, Catherine ^a   Steidl, Christian ^b,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AFM 13; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BORTEZOMIB; BRENTUXIMAB VEDOTIN; CD163 ANTIGEN; CD20 ANTIBODY; CD20 ANTIGEN; CD30 ANTIGEN; CD68 ANTIGEN; COLONY STIMULATING FACTOR 1 RECEPTOR; CYTOKINE RECEPTOR; EVEROLIMUS; GALIXIMAB; GEMCITABINE; GRANZYME B; IPILIMUMAB; IRATUMUMAB; LENALIDOMIDE; LUCATUMUMAB; NIVOLUMAB; PACRITINIB; PANOBINOSTAT; PEVONEDISTAT; PLX 3397; RITUXIMAB; SGN 30; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ADOPTIVE IMMUNOTHERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CLINICAL DECISION MAKING; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG TARGETING; GENE EXPRESSION PROFILING; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; PATIENT IDENTIFICATION; PLASMACYTOID DENDRITIC CELL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TREATMENT FAILURE; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

HODGKIN DISEASE; HUMANS; MOLECULAR TARGETED THERAPY; PROGNOSIS;

EID: 84878971606     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3064     Document Type: Article

References (63)

1. Aldinucci D, Gloghini A, Pinto A, De Filippi R, Carbone A. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol 2010;221:248-63.
2. Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol 2011;29:1812-26.
3. Hsi ED. Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: tumor and microenvironment. Leuk Lymphoma 2008;49: 1668-80.
4. Kuppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009;9:15-27.
5. Khan G. Epstein-Barr virus, cytokines, and inflammation: a cocktail for the pathogenesis of Hodgkin's lymphoma? Exp Hematol 2006;34: 399-406.
6. van den Berg A, Visser L, Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma. Am J Pathol 1999;154:1685-91. (Pubitemid 29262850)
7. Aldinucci D, Lorenzon D, Cattaruzza L, Pinto A, Gloghini A, Carbone A, et al. Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. Int J Cancer 2008;122:769-76.
8. Cattaruzza L, Gloghini A, Olivo K, Di Francia R, Lorenzon D, De Filippi R, et al. Functional coexpression of Interleukin (IL)-7 and its receptor (IL-7R) on Hodgkin and Reed-Sternberg cells: ivolvement of IL-7 in tumor cell growth and microenvironmental interactions of Hodgkin's lymphoma. Int J Cancer 2009;125:1092-101.
9. Tanijiri T, Shimizu T, Uehira K, Yokoi T, Amuro H, Sugimoto H, et al. Hodgkin's reed-sternberg cell line (KM-H2) promotes a bidirectional differentiation of CD4+CD25+Foxp3+ T cells and CD4+ cytotoxic T lymphocytes from CD4+ naive T cells. J Leukoc Biol 2007;82:576-84. (Pubitemid 47367148)
10. Farrell K, Jarrett RF. The molecular pathogenesis of Hodgkin lymphoma. Histopathology 2011;58:15-25.
11. Kim LH, Eow GI, Peh SC, Poppema S. The role of CD30, CD40 and CD95 in the regulation of proliferation and apoptosis in classical Hodgkin's lymphoma. Pathology 2003;35:428-35. (Pubitemid 37310985)
12. Walker PR, Saas P, Dietrich PY. Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J Immunol 1997;158:4521-4.
13. Verbeke CS, Wenthe U, Grobholz R, Zentgraf H. Fas ligand expression in Hodgkin lymphoma. Am J Surg Pathol 2001;25:388-94. (Pubitemid 32174208)
14. Dotti G, Savoldo B, Pule M, Straathof KC, Biagi E, Yvon E, et al. Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. Blood 2005;105:4677-84. (Pubitemid 40807289)
15. Gandhi MK, Moll G, Smith C, Dua U, Lambley E, Ramuz O, et al. Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma. Blood 2007;110: 1326-9. (Pubitemid 47281432)
16. Juszczynski P, Ouyang J, Monti S, Rodig SJ, Takeyama K, Abramson J, et al. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci U S A 2007;104:13134-9. (Pubitemid 351737605)
17. Yamamoto R, Nishikori M, Kitawaki T, Sakai T, Hishizawa M, Tashima M, et al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 2008;111: 3220-4.
18. Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010;116:3268-77.
19. Steidl C, Shah SP, Woolcock BW, Rui L, Kawahara M, Farinha P, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 2011;471:377-81.
20. SEER Cancer Statistics Review 2001-2008. National Cancer Institute. [Accessed 2012 Dec 2]. Available from: http://www.seer.cancer.gov.
21. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
22. Gascoyne RD, Rosenwald A, Poppema S, Lenz G. Prognostic biomarkers in malignant lymphomas. Leuk Lymphoma 2010;51 Suppl 1:11-9.
23. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339:1506-14.
24. Moskowitz C. Risk-adapted therapy for relapsed and refractory lymphoma using ICE chemotherapy. Cancer Chemother Pharmacol 2002;49 Suppl 1:S9-12.
25. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012;30:2183-9.
26. Bonfante V, Santoro A, Viviani S, Devizzi L, Balzarotti M, Soncini F, et al. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol 1997;15:528-34. (Pubitemid 27074219)
27. Longo DL, Duffey PL, Young RC, Hubbard SM, Ihde DC, Glatstein E, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol 1992;10: 210-8.
28. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351: 2159-69. (Pubitemid 39507628)
29. Alvaro T, Lejeune M, Salvado MT, Bosch R, Garcia JF, Jaen J, et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005;11:1467-73. (Pubitemid 40315228)
30. Diepstra A, van Imhoff GW, Karim-Kos HE, van den Berg A, te Meerman GJ, Niens M, et al. HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma. J Clin Oncol 2007;25:3101-8. (Pubitemid 47218058)
31. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010;362:875-85.
32. Kamper P, Bendix K, Hamilton-Dutoit S, Honoré B, Nyengaard JR, d'Amore F. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica 2011;96:269-76.
33. Tan KL, Scott DW, Hong F, Kahl BS, Fisher RI, Bartlett NL, et al. Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood 2012;120:3280-7.
34. Chetaille B, Bertucci F, Finetti P, Esterni B, Stamatoullas A, Picquenot JM, et al. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood 2009;113:2765-3775.
35. Younes A, Romaguera J, Hagemeister F, McLaughlin P, Rodriguez MA, Fiumara P, et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 2003;98:310-4. (Pubitemid 36828455)
36. Jones RJ, Gocke CD, Kasamon YL, Miller CB, Perkins B, Barber JP, et al. Circulating clonotypic B cells in classic Hodgkin lymphoma. Blood 2009;113:5920-6.
37. Rassidakis GZ, Medeiros LJ, Viviani S, Bonfante V, Nadali GP, Vassilakopoulos TP, et al. CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome. J Clin Oncol 2002;20:1278-87. (Pubitemid 34177434)
38. Buglio D, Georgakis GV, Hanabuchi S, Arima K, Khaskhely NM, Liu YJ, et al. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 2008;112:1424-33.
39. Weihrauch MR, Manzke O, Beyer M, Haverkamp H, Diehl V, Bohlen H, et al. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor. Cancer Res 2005;65:5516-9. (Pubitemid 40911150)
40. Ansell SM, Maurer MJ, Ziesmer SC, Slager SL, Habermann TM, Link BK, et al. Pretreatment serum cytokines predict early disease relapse and a poor prognosis in newly diagnosed classical Hodgkin lymphoma (cHL) patients [abstract]. In: Proceedings of the 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, CA. Washington, DC: ASH; 2011. Abstract nr 429.
41. Ouyang J, Plutschow A, Pogge E, Ponader S, Rabinovich G, Neuberg DS, et al. Galectin-1 serum levels reflect tumor burden and adverse clinical features in Hodgkin lymphoma [abstract]. In: Proceedings of the 54th ASH Annual Meeting and Exposition; 2012 Dec 8-12; Atlanta, GA. Washington, DC: ASH; 2012. Abstract nr 51.
42. Steidl C, Diepstra A, Lee T, Chan FC, Farinha P, Tan K, et al. Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. Blood 2012;120:3530-40.
43. Scott DW, Chan FC, Hong F, Rogic S, Tan KL, Meissner B, et al. Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical hodgkin lymphoma. J Clin Oncol 2012;31:692-700.
44. Ansell SM, Horwitz SM, Engert A, Khan KD, Lin T, Strair R, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007; 25:2764-9. (Pubitemid 47123185)
45. Forero-Torres A, Leonard JP, Younes A, Rosenblatt JD, Brice P, Bartlett NL, et al. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009;146:171-9.
46. Blum KA, Jung SH, Johnson JL, Lin TS, Hsi ED, Lucas DM, et al. Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcgammaRIIIa-158 V/F polymorphism. Ann Oncol 2010;21:2246-54.
47. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812-21.
48. Fanale MA, Forero-Torres A, Rosenblatt JD, Advani RH, Franklin AR, Kennedy DA, et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic Malignancies. Clin Cancer Res 2012;18:248-55.
49. Smith SM, Schöder H, Johnson JL, Jung SH, Bartlett NL, Cheson BD. The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B50602 (Alliance). Leuk lymphoma. Epub 2012 Jan 4.
50. Nozawa Y, Wakasa H, Abe M. Costimulatory molecules (CD80 and CD86) on Reed-Sternberg cells are associated with the proliferation of background T cells in Hodgkin's disease. Pathol Int 1998;48: 10-4.
51. Rothe A, Younes A, Reiners KS, Dietlein M, Eichenauer DA, Kessler J, et al. A phase I study with the bispecific anti-CD30 x anti-CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma [abstract]. In: Proceedings of the 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, CA. Washington, DC: ASH; 2011. Abstract nr 3709.
52. Kashkar H, Deggerich A, Seeger JM, Yazdanpanah B, Wiegmann K, Haubert D, et al. NF-kappaB-independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs. Blood 2007;109:3982-8. (Pubitemid 46641751)
53. Blum KA, Johnson JL, Niedzwiecki D, Canellos GP, Cheson BD, Bartlett NL. Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and Leukemia Group B protocol 50206. Leuk Lymphoma 2007;48:1313-9. (Pubitemid 47079358)
54. Derenzini E, Lemoine M, Buglio D, Katayama H, Ji Y, Davis RE, et al. The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma. Blood Cancer J 2011;1:e46.
55. Younes A, Fanale MA, McLaughlin P, Copeland A, Zhu J, de Castro Faria S. Phase I study of a novel oral JAK-2 inhibitor SB1518 in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes [abstract]. In: Proceedings of the 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; Orlando, FL. Washington, DC: ASH; 2011. Abstract nr 2830.
56. Johnston PB, Pinter-Brown L, Rogerio J, Warsi G, Graham A, Ramchandren R. Open-label, single-arm, phase II study of everolimus in patients with relapsed/refractory classical Hodgkin lymphoma [abstract]. In: Proceedings of the 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, CA. Washington, DC: ASH; 2011. Abstract nr 2717.
57. Younes A, Copeland A, Fanale MA, Fayad L, Romaguera JE, Kwak LW, et al. Safety and efficacy of the novel combination of panobinostat (LBH589) and everolimus (RAD001) in relapsed/refractory hodgkin and non-hodgkin lymphoma [abstract]. In: Proceedings of the 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, CA. Washington, DC: ASH; 2011. Abstract nr 3718.
58. Kirschbaum MH, Goldman BH, Zain JM, Cook JR, Rimsza LM, Forman SJ, et al. A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517. Leuk Lymphoma 2012;53:259-62.
59. Younes A, Sureda A, Ben-Yehuda D, Zinzani PL, Ong TC, Prince HM, et al. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol 2012;30:2197-203.
60. Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011;118: 5119-25.
61. Moskowitz CH, Younes A, de Vos S, Bociek RG, Gordon LI, Witzig TE, et al. CSF1R Inhibition by PLX3397 in patients with relapsed or refractory Hodgkin lymphoma: results from a phase 2 single agent clinical trial [abstract]. In: Proceedings of the 54th ASH Annual Meeting and Exposition; 2012 Dec 8-12; Atlanta, GA. Washington, DC: ASH; 2012. Abstract nr 1638.
62. Bollard CM, Gottschalk S, Leen AM, Weiss H, Straathof KC, Carrum G, et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 2007;110:2838-45. (Pubitemid 350006936)
63. Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau A, et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med 2004;200:1623-33. (Pubitemid 40094186)